Desipramine
Desipramine, Norpramin (desipramine) is a small molecule pharmaceutical. Desipramine was first approved as Pertofrane on 1982-01-01. It is used to treat attention deficit disorder with hyperactivity, depressive disorder, pain, psychotic affective disorders, and substance-related disorders in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target equilibrative nucleoside transporter 4, G protein-activated inward rectifier potassium channel 2, and G protein-activated inward rectifier potassium channel 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Desipramine, Norpramin (discontinued: Desipramine, Pertofrane)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Desipramine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NORPRAMIN | Validus Pharmaceuticals | N-014399 RX | 1982-01-01 | 6 products, RLD |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| desipramine hcl | ANDA | 2022-11-16 |
| desipramine hydrochloride | ANDA | 2024-10-09 |
| norpramin | New Drug Application | 2023-12-12 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 4 | 1 | 3 | 2 | 3 | 13 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 2 | 3 | 2 | 8 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 1 | 2 | — | 4 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | 1 | — | 3 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 1 | 1 | 2 |
| Atrophy | D001284 | — | — | — | — | — | 1 | — | 1 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | 1 | — | 1 |
| Neuroaxonal dystrophies | D019150 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | 1 | — | — | 2 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | 1 | — | 1 | 2 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | 1 | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
| Herpes zoster | D006562 | EFO_0006510 | B02 | — | — | 1 | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | 1 | — | — | 1 |
| Gastrointestinal diseases | D005767 | — | — | — | — | 1 | — | — | 1 |
| Abdominal pain | D015746 | HP_0002027 | R10.9 | — | — | 1 | — | — | 1 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | 1 | — | — | 1 |
| Colonic diseases | D003108 | — | — | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | — | 3 | — | — | — | 3 |
| Back pain | D001416 | HP_0003418 | M54 | — | 2 | — | — | — | 2 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 2 | — | — | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | — | — | 1 | 2 |
| Dual (psychiatry) diagnosis | D017831 | — | — | — | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Sciatica | D012585 | HP_0011868 | M54.3 | — | 1 | — | — | — | 1 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | 1 | — | — | — | 1 |
| Apnea | D001049 | HP_0002104 | R06.81 | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | — | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Multiple myeloma | D009101 | — | C90.0 | — | — | — | — | 1 | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | — | — | — | 1 | 1 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | — | — | 1 | 1 |
| Vulvar diseases | D014845 | — | — | — | — | — | — | 1 | 1 |
| Vulvar vestibulitis | D054515 | — | N94.810 | — | — | — | — | 1 | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | — | 1 | 1 |
| Personality disorders | D010554 | HP_0012075 | F60.6 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Desipramine |
| INN | desipramine |
| Description | Desipramine is a dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group. It has a role as an adrenergic uptake inhibitor, a serotonin uptake inhibitor, a cholinergic antagonist, an alpha-adrenergic antagonist, a H1-receptor antagonist, an EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor, an antidepressant and a drug allergen. It is a dibenzoazepine and a secondary amino compound. |
| Classification | Small molecule |
| Drug class | antidepressants (imipramine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNCCCN1c2ccccc2CCc2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 50-47-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL72 |
| ChEBI ID | 47781 |
| PubChem CID | 2995 |
| DrugBank | DB01151 |
| UNII ID | TG537D343B (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Desipramine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,722 documents
View more details
Safety
Black-box Warning
Black-box warning for: Desipramine hydrochloride, Norpramin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
654 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use